Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * |
Title | Medicxi |
Description | About --> Toggle navigation About Approach Team Companies News Room Contact --> --> --> --> Granular Therapeutics to accelerate development of ne |
Keywords | N/A |
WebSite | medicxi.com |
Host IP | 81.23.73.70 |
Location | Switzerland |
Site | Rank |
US$4,731,185
Last updated: 2023-04-27 03:57:19
medicxi.com has Semrush global rank of 2,237,136. medicxi.com has an estimated worth of US$ 4,731,185, based on its estimated Ads revenue. medicxi.com receives approximately 545,906 unique visitors each day. Its web server is located in Switzerland, with IP address 81.23.73.70. According to SiteAdvisor, medicxi.com is safe to visit. |
Purchase/Sale Value | US$4,731,185 |
Daily Ads Revenue | US$4,368 |
Monthly Ads Revenue | US$131,018 |
Yearly Ads Revenue | US$1,572,209 |
Daily Unique Visitors | 36,394 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
medicxi.com. | A | 598 | IP: 81.23.73.70 |
medicxi.com. | NS | 3600 | NS Record: ns24.domaincontrol.com. |
medicxi.com. | NS | 3600 | NS Record: ns23.domaincontrol.com. |
medicxi.com. | MX | 3600 | MX Record: 10 eu-smtp-inbound-1.mimecast.com. |
medicxi.com. | MX | 3600 | MX Record: 10 eu-smtp-inbound-2.mimecast.com. |
medicxi.com. | TXT | 3600 | TXT Record: google-site-verification=p1w2JRYqAqK38jIS6xT5-PnWUl6SgLPXvoCwYmUthCU |
medicxi.com. | TXT | 3600 | TXT Record: ZOOM_verify_e5TxSvt1MnGAQ8gF57Hg41 |
medicxi.com. | TXT | 3600 | TXT Record: v=spf1 include:_spf.google.com include:_netblocks.mimecast.com ~all |
--> Toggle navigation About Approach Team Companies News Room Contact --> --> --> --> Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases Press Release --> Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology Press Release --> Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody Press Release --> Medicxi portfolio company MiroBio to be acquired by Gilead Sciences for approximately $405 million Press Release --> Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) Press Release --> Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants Press Release --> |
HTTP/1.1 302 Found Date: Wed, 20 Oct 2021 11:05:49 GMT Server: Apache Location: https://www.medicxi.com/ Cache-Control: max-age=86400 Expires: Thu, 21 Oct 2021 11:05:49 GMT Content-Type: text/html; charset=iso-8859-1 HTTP/1.1 200 OK Date: Wed, 20 Oct 2021 11:05:50 GMT Server: Apache X-Powered-By: PHP/5.6.40 Content-Type: text/html; charset=UTF-8 |
Domain Name: MEDICXI.COM Registry Domain ID: 1962771277_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2020-09-23T06:26:15Z Creation Date: 2015-09-23T12:42:03Z Registry Expiry Date: 2025-09-23T12:42:03Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS23.DOMAINCONTROL.COM Name Server: NS24.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-09T00:01:51Z <<< |